595847 Disclosed is a crystalline form of the compound (2S)-2-[{ (S)-2-[{ (2-methyl-thiazol-5-yl)carbonyl} amino]-3-methoxy-1-oxo-propyl} amino]-N-((S)-1-((R)-2-methyloxiran-2-yl)-1-oxo-3-phenylpropan-2-yl)-3-methoxy-propanamide having the structure as represented by formula (II) wherein the crystalline compound has 2theta values 8.94； 9.39； 9.76； 10.60； 11.09； 12.74； 15.27； 17.74； 18.96； 20.58； 20.88； 21.58； 21.78； 22.25； 22.80； 24.25； 24.66； 26.04； 26.44； 28.32； 28.96； 29.65； 30.22； 30.46； 30.78； 32.17； 33.65； 34.49； 35.08； 35.33； 37.85； and 38.48； and has a melting point of about 145 to about 150°C； said crystalline form can be obtained by (i) preparing a solution of a compound of Formula (II) in an organic solvent such as acetonitrile, ethyl acetate, heptanes, hexanes, isopropyl acetate, methanol, methylethyl ketone, tetrahydrofuran, toluene, water, or any combination thereof； (ii) bringing the solution to supersaturation to cause formation of crystals； and (iii) isolating the crystals.
